Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
The study heated Cannabis sativa extracts at 80, 95, 110, 130, and 145 °C for up to 60 minutes and measured acidic and neutral cannabinoids with an advanced UHPSFC/PDA‑MS lab method. Concentrations changed in an exponential way, which fits a first‑order (or pseudo‑first‑order) reaction model. The team calculated rate constants…
This review explains how the mushroom drugs psilocybin and psilocin are broken down in the body. Psilocybin is mainly a pro-drug that enzymes convert into the active compound psilocin. Psilocin is then further changed, and the main substance found in urine is psilocin-O-glucuronide, which matters for clinical and forensic testing.…
This report describes 33 open-label treatments with the alkaloid ibogaine given for acute heroin withdrawal in non-medical settings. In 25 of the 33 people, visible signs of opioid withdrawal stopped within 24 hours and stayed absent during 72 hours of observation. The authors note the results are from uncontrolled, non-clinical…
Researchers reviewed studies of drugs that act on serotonin (so-called serotonergic psychedelics) and MDMA. They found that harms and bad reactions are not clearly defined in these studies and are probably reported less often than they actually happen. Some intense or frightening experiences during treatment might help people heal, but…
This review explains the fast-growing problem of so-called "legal highs", which are better called novel psychoactive substances or NPS. Unknown labs keep making slightly different chemicals to avoid bans, and this led to about 80 new substances being spotted in one year. The paper groups these drugs into five main…
Cannabis makes more than 120 “minor” cannabinoids that appear in smaller amounts than THC and CBD and come from a parent compound called cannabigerolic acid (CBGA). Early lab and clinical work shows these minor cannabinoids can activate or block many biological targets (for example CB1 and CB2 receptors, TRP channels,…
There is a large body of research but no clear answer about cannabis safety and benefits. More than 60 systematic reviews exist, yet findings are mixed because studies use different methods and cannabis products vary a lot. Research shows short- and long-term effects on the heart, lungs, immune system, sleep,…
This review says that the main active part of cannabis, THC, acts at the brain's CB1 receptor to produce rewarding effects, reinforce smoking, and can lead to dependence and withdrawal. Evidence comes from animal and human studies. Higher THC strength raises blood THC levels and may raise the chance of…
This review explains how the main cannabis chemicals, especially THC and CBD, act in the body and how the body absorbs and breaks them down. THC and CBD bind to cannabinoid receptors (CB1 and CB2) in the brain and other organs. Inhaling THC delivers it to blood and brain fast…
This article explains how workplace drug testing for marijuana usually looks for an inactive THC metabolite in urine. A positive urine test does not prove a person was impaired or recently using marijuana. Tests usually start with a quick screen and then use a lab confirmation. Urine is the most…
This review looked at 47 completed clinical trials of cannabinoids (mainly THC and CBD) for brain and nerve conditions. Some trials showed benefits for symptoms like spasticity in multiple sclerosis and for certain forms of epilepsy, but results for pain were mixed. The authors say the evidence is promising but…
This paper reviews research on ayahuasca and its main ingredient, DMT, and how they might help with mental health. Ayahuasca is a plant brew that makes DMT work when you drink it because it also contains chemicals that stop the body from breaking DMT down. Lab studies and a small…
